PUBLISHER: The Business Research Company | PRODUCT CODE: 1751087
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751087
Prothrombin complex concentrate (PCC) is a medication that contains clotting factors, used to treat or prevent bleeding in patients with coagulation disorders. It is administered intravenously to quickly restore clotting factor levels in conditions such as hemophilia, warfarin reversal, and severe bleeding episodes.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main types of prothrombin complex concentrate products include 3-factor prothrombin complex concentrates (3F-PCC), 4-factor prothrombin complex concentrates (4F-PCC), and other variations. 3-factor prothrombin complex concentrates (3F-PCC) are blood products containing clotting factors II, IX, and X, used to manage bleeding without the need for factor VII supplementation. These are indicated for conditions such as hemorrhagic episodes in factor IX deficiency (hemophilia B), trauma, life-threatening coagulopathy with acute bleeding, warfarin-associated acute life-threatening bleeding, and non-warfarin anticoagulant reversal during acute bleeding. The routes of administration include intravenous (IV), subcutaneous, and intramuscular injections, with usage in hospitals, ambulatory surgical centers, specialty clinics, and other healthcare facilities.
The prothrombin complex concentrate market research report is one of a series of new reports from The Business Research Company that provides prothrombin complex concentrate market statistics, including the prothrombin complex concentrate industry global market size, regional shares, competitors with the prothrombin complex concentrate market share, detailed prothrombin complex concentrate market segments, market trends, and opportunities, and any further data you may need to thrive in the prothrombin complex concentrate industry. This prothrombin complex concentrate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The prothrombin complex concentrate market size has grown strongly in recent years. It will grow from$1.29 billion in 2024 to $1.39 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth during the historic period can be attributed to factors such as the rising prevalence of bleeding disorders, increased use of PCC in warfarin reversal, greater awareness of coagulation therapies, expansion of surgical procedures, and a higher number of trauma cases.
The prothrombin complex concentrate market size is expected to see strong growth in the next few years. It will grow to$1.86 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth during the forecast period can be attributed to factors such as the growing demand for rapid coagulation therapies, the increasing prevalence of hemophilia and liver diseases, rising adoption in emergency medicine, expanding applications in cardiac surgeries, and higher healthcare expenditures. Key trends during this period include the integration of AI-driven diagnostics, advancements in recombinant coagulation factors, next-generation recombinant PCCs, customized dosing algorithms, and progress in blood plasma products.
The growing prevalence of bleeding disorders is anticipated to drive the expansion of the prothrombin complex concentrate market in the coming years. Bleeding disorders are conditions in which blood does not clot properly, leading to excessive bleeding due to missing or malfunctioning clotting factors or platelets. The rise in bleeding disorders is mainly attributed to the increasing prevalence of genetic conditions such as hemophilia, more cases of liver diseases, the wider use of anticoagulant medications, and higher rates of vitamin K deficiencies. Prothrombin complex concentrate helps manage bleeding disorders by quickly replenishing the clotting factors essential for blood coagulation and hemostasis. For example, in November 2023, a U.S.-based medical library, the National Library of Medicine, reported a study conducted in 2022 across 87 treatment centers in 40 countries. This study involved 10,276 individuals with hemophilia, with 49% of participants having severe hemophilia. The majority (99%) of the participants were male, and 85% had hemophilia A. Additionally, 67% of the patients were from low- and middle-income countries. Thus, the increasing prevalence of bleeding disorders is a significant driver for the prothrombin complex concentrate market.
The rising prescription rate of anticoagulants is expected to further boost the growth of the prothrombin complex concentrate market. Anticoagulants are substances that prevent or reduce blood clot formation by inhibiting coagulation factors or platelet aggregation. The increased prescription of anticoagulants is primarily driven by the growing prevalence of cardiovascular diseases, an aging population, broader clinical indications, better screening programs, and advancements in anticoagulant therapy. Prothrombin complex concentrate helps counteract the effects of anticoagulants by quickly replenishing clotting factors and restoring hemostasis in patients experiencing excessive bleeding or requiring urgent surgical intervention. For instance, in November 2023, the National Health Service (NHS), a UK-based government body, reported that in 2022, 460,000 additional people began using anticoagulant medications, with over 24 million prescriptions issued to patients. This helped prevent an estimated 17,000 strokes and 4,000 deaths. Consequently, the increasing prescription rate of anticoagulants is contributing to the growth of the prothrombin complex concentrate market.
Leading companies in the prothrombin complex concentrate market are developing innovative formulations, such as lyophilized powder, to improve stability, enhance storage, and simplify administration. The lyophilized powder is a freeze-dried formulation that removes water to extend shelf life while maintaining potency. This enables better storage conditions and rapid reconstitution for emergency use. For example, in July 2023, Octapharma USA Inc., a biotechnology company based in the U.S., received FDA approval for Balfaxar, a four-factor prothrombin complex concentrate (4F-PCC) for the urgent reversal of warfarin during surgeries and invasive procedures. The approval was based on the results from the LEX-209 trial, which demonstrated 94.6% hemostatic efficacy, proving it to be as effective as Kcentra. This development highlights the industry's focus on advancing coagulation therapies to improve patient outcomes in critical care environments.
Major players in the prothrombin complex concentrate market are Pfizer Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, CSL Behring GmbH, Intas Pharmaceuticals Ltd, Baxter International Inc, Grifols S.A., Octapharma AG, Kedrion S.p.A, Haemonetics Corporation, Green Cross Corporation, Shanghai RAAS Blood Products Co. Ltd, Emergent BioSolutions, LFB Group, Hualan Biological Engineering Chongqing Co. Ltd., Sanquin Blood Supply Foundation, Bio Products Laboratory Ltd (BPL), Prothya Biosolutions B.V., and China Biologic Products Holdings Inc.
North America was the largest region in the prothrombin complex concentrate market in 2024. The regions covered in prothrombin complex concentrate report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the prothrombin complex concentrate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The prothrombin complex concentrate market consists of sales of activated PCC, recombinant coagulation factors, combination hemostatic agents, warfarin reversal, and emergency coagulation therapy products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Prothrombin Complex Concentrate Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on prothrombin complex concentrate market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for prothrombin complex concentrate ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prothrombin complex concentrate market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.